Dyspnea is distressing in palliative patients with end-stage heart failure and many are hospitalized to optimize this symptom. We hoped to conduct a pilot study to determine whether the administration of intranasal fentanyl would decrease activity-induced dyspnea in this patient population.
Methods:
Patients performed two 6-minute walk tests with and without the administration of 50 μg of intranasal fentanyl. Vital signs were recorded before and after each walk, as were participant reported dyspnea and adverse events scores.
Results:
Twenty-four patients were screened, 13 were deemed eligible, and 6 completed the study. Dyspnea scores changed from a mean of 6.00 immediately after the walk without fentanyl to a mean of 3.83 after the walk with fentanyl (P = .048). Mean respiratory rate decreased from 21.0 to 18.7 (P = .034) breaths per minute and was considered a favorable outcome by the participants. Distance walked did not significantly increase with the fentanyl pretreatment (136.0-144.2 m; P = .283), although the participants reported feeling better while walking a similar distance.
Conclusions:
In this pilot study, the preadministration of intranasal fentanyl prior to activity in palliative, end-stage hospitalized heart failure patients, safely reduced tachypnea, and the feeling of shortness of breath. This approach may help palliate advanced heart failure patients by alleviating symptoms brought on by exertional activities.
EscalanteCPMartinCGEltingLS. Dyspnea in cancer patients. Etiology, resource utilization and survival implications in a managed care world. Cancer. 1996;78(6):1314–1319.
2.
NelsonKWalshD. Management of dyspnea in advanced cancer. Cancer Bulletin. 1991;43:423–426.
3.
MularskiRACampbellMLAschSM. A review of quality of care evaluation for the palliation of dyspnea. Am J Respir Crit Care Med. 2010;181(6):534–538.
4.
JanssenDJSpruitMAWoutersEFScholsJM. Daily symptom burden in end-stage chronic organ failure: a systematic review. Palliat Med. 2008;22(8):938–948.
5.
EzekowitzJAO’MearaEMcDonaldMA. 2017 Comprehensive update of the Canadian Cardiovascular Society Guidelines for the management of heart failure. Can J Cardiol. 2017;33(11):1342–1433.
6.
JohnsonMJMcDonaghTAHarknessA. Morphine for the relief of breathlessness in patients with chronic heart failure: a pilot study. Eur J Heart Fail2002;4(6):753–756.
7.
OxberrySGTorgersonDJBlandJM. Short-term opioids for breathlessness in stable chronic heart failure: a randomized controlled trial. Eur J Heart Fail2011;13(9):1006–1012.
8.
OxberrySGBlandJMClarkALClelandJGJohnsonMJ. Repeat dose opioids may be effective for breathlessness in chronic heart failure if given for long enough. J Palliat Med2013;16(3):250–255.
9.
WilliamsSGWrightDJMarshallP. Safety and potential benefits of low dose diamorphine during exercise in patients with chronic heart failure. Heart. 2003;89(9):1085–1086.
10.
ChuaTPHarringtonDPonikowskiPWebb-PeploeKPoole-WilsonPACoatsAJ. Effects of dihydrocodeine on chemosensitivity and exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol. 1997;29(1):147–152.
BittnerV. Six-minute walk test in patients with cardiac dysfunction. Cardiologia. 1997;42(9):897–902.
13.
PeetersPMetsT. The 6 minute walk as an appropriate exercise test in elderly patients with chronic heart failure. J Gerontol A Bio Sci Med Sci1996;51(4).M147–M151
14.
DaleOHjortkjaerRKharaschED. Nasal administration of opioids for pain management in adults. Acta Anaesthesiol Scand. 2002;46(7):759–770.
15.
RogríguezDUrrutiaGEscobarYMoyaJMurilloM. Efficacy and safety of oral or nasal fentanyl for treatment of breakthrough pain in cancer patients: a systematic review. J Pain Palliat Care Pharmacother. 2015;29(3):228–246.
16.
WattsPSmithAPerelmanM. Nasal delivery of fentanyl. Drug Deliv Transl Res. 2013;3(1):75–83.
17.
NaveRSchmittHPopperL. Faster absorption and higher systemic bioavailability of intranasal fentanyl spray compared to oral transmucosal fentanyl citrate in healthy subjects. Drug Deliv. 2013;20(5):216–223.
18.
LimSPaechMJSunderlandB. Pharmacokinetics of nasal fentanyl. J Pharm Pract Res. 2003;33:59–63.
19.
FosterDUptonRChristrupLPopperL. Pharmacokinetics and pharmacodynamics of intranasal versus intravenous fentanyl in patients with pain after oral surgery. Ann Pharmacother. 2008;42(10):1380–1387.
20.
MercadanteSVellucciRCuomoA. Long-term efficacy and tolerability of intranasal fentanyl in the treatment of breakthrough cancer pain. Support Care Cancer. 2015;23(5):1349–1354.
21.
Veldhorst-JanssenNMFiddelersAAZandstraH. Patient satisfaction with intranasal fentanyl for breakthrough pain. J Palliat Med. 2012;15(6):631–632.
22.
BrueraEKuehnNMillerMJSelmserPMacmillanK. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care. 1991;7(2):6–9.
23.
DuHWonggomPTongpethJClarkRA. Six-minute walk test for assessing physical functional capacity in chronic heart failure. Curr Heart Fail Rep. 2017;14(3):158–166.
24.
ShoemakerMJCurtisABVangsnesEDickinsonMG. Clinically meaningful change estimates for the six-minute walk test and daily activity in individuals with chronic heart failure. Cardiopulm Phys Ther J. 2013;24(3):21–29.
25.
SchoverREvansKGiuglianiRNobleIBhattacharyaK. Minimal clinically important difference for the 6-min walk test: literature review and application to Morquio A syndrome. Orphanet J Rare Dis. 2017;12(1):78.
26.
JohnsonMJCurrowDC. Minimal clinically important difference and Edmonton Symptom Assessment Scale. Cancer. 2016;122(1):158–159.
27.
AnderDSAisikuIPRatcliffJJToddKHGotschK. Measuring the dyspnea of decompensated heart failure with a visual analog scale: how much improvement is meaningful?Congest Heart Fail. 2004;10(4):188–191.
28.
HuiDKilgoreKParkMWilliamsJLiuDBrueraE. Impact of prophylactic fentanyl pectin nasal spray on exercise-induced episodic dyspnea in cancer patients: a double-blind, randomized controlled trial. J Pain Symptom Manage. 2016;52(4):459–468.
29.
HuiDKilgoreKFrisbee-HumeS. Effect of prophylactic fentanyl buccal tablet on episodic exertional dyspnea: a pilot double-blind randomized controlled trial. J Pain Symptom Manage. 2017;54(6):798–805.
30.
American Thoracic Society. ATS Statement. Guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111–117.
31.
IngleLClelandJGClarkAL. The relation between repeated 6-minute walk test performance and outcome in patients with chronic heart failure. Ann Phys Rehabil Med. 2014;57(4):244–253.
32.
BittnerVWeinerDHYusufS. Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. SOLVD Investigators. JAMA. 1993;270(14):1702–1707.
33.
SmithTJCoynePFrenchWRamakrishnanVCorriganP. Failure to accrue to a study of nebulized fentanyl for dyspnea: lessons learned. J Palliat Med. 2009;12(9):771–772.
WuGSandersonBBittnerV. The 6-minute walk test: how important is the learning effect?AM Heart J. 2003;146(1):129–133.
36.
PinnaGDOpasichCMazzaATangentiAMaestriRSanaricoM. Reproducibility of the six-minute walking test in chronic heart failure patients. Stat Med. 2000;19(22):3087–3094.
